Category: Cancer

Home / Established Year

Repotrectinib has received accelerated approval for adult and pediatric patients with NTRK gene fusion-positive solid tumors

Repotrectinib has received accelerated approval from the USFDA for adult and pediatric patients with NTRK gene fusion-positive solid tumors

  June 2024: The Food and Drug Administration (FDA) has given accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for the treatment of solid tumors in adult and pediatric patients aged 12 and abov..

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients The Food and Drug Administration has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) as a way to ..

Understanding BCMA: A Revolutionary Target in Cancer Treatment
,

Understanding BCMA: A Revolutionary Target in Cancer Treatment

Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted repercussions. One such intri..

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?

  Targeted Therapy in Advanced Cancer: A Precision Approach to Treatment Targeted therapy has significantly transformed the therapeutic options for advanced cancer in the field of oncology. Targeted therapy differs from con..

Outline: Understanding Survivorship in the Context of Advanced Cancers The Landscape of Long-Term Care for Advanced Cancer Patients Navigating the Emotional and Psychological Journey The Future of Care Coordination and Survivorship Plans

Survivorship and long-term care in advanced cancers

    Understanding Survivorship in the Context of Advanced Cancers Survivorship, once a term associated predominantly with those in remission, has evolved. Today, it encompasses a multifaceted journey that includes i..

Cancer statistics in India 2024

Cancer statistics in India 2024: Incidence, estimates and projections

Cancer incidence, statistics, and estimates 2024: Results from National Cancer Registry Program Cancer incidence rates are increasing at an alarming rate in India, and are anticipated to grow by 12% over the next five years. As a..

India declared cancer capital of the world - Apollo report

India declared cancer capital of the world – Apollo report

India declared cancer capital of the world India was designated as the "cancer capital of the world" in the 4th edition of Apollo Hospitals' Health of the Nation Report, which was published on World Health Day 2024. According ..

Understanding relations between MRD and CAR T-Cell therapy

Understanding relations between MRD and CAR T-Cell therapy

What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..

Lifileucel is approved by the USFDA for unresectable or metastatic melanoma

Lifileucel is approved by the USFDA for unresectable or metastatic melanoma

The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..

Tepotinib is approved by the USFDA for metastatic, non-small cell lung cancer

Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer

The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..

Newer
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy